Cytokinetics Inc (NASDAQ: CYTK) on Tuesday, plunged -3.95% from the previous trading day, before settling in for the closing price of $64.13. Within the past 52 weeks, CYTK’s price has moved between $29.31 and $69.33.
A company in the Healthcare sector has dropped its sales by -20.02% annually for the last half of the decade. The company achieved an average annual earnings per share of -18.71%. With a float of $119.85 million, this company’s outstanding shares have now reached $122.12 million.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cytokinetics Inc is 1.98%, while institutional ownership is 115.57%. The most recent insider transaction that took place on Dec 08 ’25, was worth 68,730. In this transaction EVP, Chief Commercial Officer of this company sold 1,042 shares at a rate of $65.96, taking the stock ownership to the 50,660 shares. Before that another transaction happened on Dec 05 ’25, when Company’s EVP, Chief Commercial Officer sold 52,486 for $65.95, making the entire transaction worth $3,461,452. This insider now owns 50,660 shares in total.
Cytokinetics Inc (CYTK) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.26 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.17) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.57% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Cytokinetics Inc (CYTK) is currently performing well based on its current performance indicators. A quick ratio of 6.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 86.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.31, a number that is poised to hit -1.40 in the next quarter and is forecasted to reach -5.61 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.67 million. That was inferior than the volume of 1.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.12%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 78.79%, which indicates a significant increase from 3.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.55 in the past 14 days, which was higher than the 2.29 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.00, while its 200-day Moving Average is $44.72. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $64.27. Second resistance stands at $66.93. The third major resistance level sits at $68.41. If the price goes on to break the first support level at $60.12, it is likely to go to the next support level at $58.64. The third support level lies at $55.98 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
Market capitalization of the company is 7.53 billion based on 122,265K outstanding shares. Right now, sales total 18,470 K and income totals -589,530 K. The company made 1,940 K in profit during its latest quarter, and -306,180 K in sales during its previous quarter.
